Scope and Claim Analysis for US Patent 11,696,919 (Topical Polyaphron Dispersion of Calcipotriol/Betamethasone)
US 11,696,919 centers on a topical combination composition that uses a polyaphron dispersion (continuous aqueous phase + discontinuous oil phase(s)) to deliver a defined calcipotriol/betamethasone regimen with tightly constrained excipient chemistry (alpha-tocopherol, butylated hydroxyanisole) and pH. Claim 1 is the key independent claim; dependent claims narrow oil-phase partitioning of actives/antioxidants, specific oil blends (CCT and isopropyl myristate at defined ratios), and stability/pH/formulation parameters that can materially affect infringement proof, design-around options, and freedom-to-operate.
What is the scope of claims 1–11 for US 11,696,919?
Claim 1 (independent): What is protected in the broadest sense?
Claim 1 is a composition claim for topical use, limited by six formulation “pillars”:
-
Dosage form / physical structure
- “composition for topical application comprising a polyaphron dispersion”
- polyaphron dispersion must include:
- continuous aqueous phase
- at least one discontinuous oil phase
-
Actives and quantitative ranges
- Calcipotriol: 0.001 to 0.01 wt%
- Betamethasone dipropionate: 0.001 to 0.01? (your text states calcipotriol and betamethasone dipropionate in the same “0.001 to 0.01 wt %” band)
- Alpha-tocopherol: 0.001 to 0.005 wt%
- Butylated hydroxyanisole (BHA): 0.05 to 0.5 wt%
-
pH requirement
- Composition pH is 7.75 ± 0.5 (so nominally ~7.25 to 8.25)
-
Topical end-use
- “for topical application” is a use limitation, but the claim is still fundamentally about the composition.
Infringement practical meaning: To read on claim 1, an accused product must show (i) polyaphron microstructure with continuous aqueous + discontinuous oil phases, (ii) the four ingredient classes in the specified concentration bands, and (iii) the specified pH window.
Claim 2: How does pH narrow?
- Claim 2: pH is 7.75 ± 0.25 (roughly 7.50 to 8.00)
This is a narrower subgroup of claim 1, useful for litigation as a fallback if a defendant’s pH sits closer to the center.
Claim 3: How does betamethasone concentration narrow?
- Claim 3: formulation comprises by weight:
- Betamethasone (not explicitly “dipropionate” in your pasted claim): 0.02 to 0.1 wt%
Claim-relationship note: Claim 3 is a dependent claim that may create a range hierarchy:
- Claim 1 appears to cap betamethasone dipropionate at 0.01 wt%, while claim 3 recites 0.02 to 0.1 wt%. If that is accurate as text, it creates tension in internal consistency (and could mean the transcription merges two versions or claim amendments). For infringement analysis, courts will construe claims as written in the issued patent. The practical impact is that claim 3 may require a betamethasone level outside claim 1’s stated range, which can affect which claim(s) are actually enforceable against a product.
Claim 4: What is the partitioning requirement?
- Claim 4: At least one of the following must be true (note the “and/or” structure):
- ≥ 60 wt% of calcipotriol is in at least one discontinuous oil phase, and/or
- ≥ 60 wt% of betamethasone dipropionate is in at least one discontinuous oil phase, and/or
- ≥ 60 wt% of alpha-tocopherol is in at least one discontinuous oil phase, and/or
- ≥ 60 wt% of BHA is in at least one discontinuous oil phase
Infringement proof impact: This claim drives the micro-partitioning and composition-to-phase distribution. It shifts the dispute from “is the product polyaphron and within overall concentration ranges” toward “can the accused product demonstrate that a majority of at least one specified component is located in the oil droplets/discontinuous phase(s).”
Claim 5: Oil-phase composition and ratio (CCT + IPM)
- Claim 5: At least one discontinuous oil phase comprises:
- medium chain triglycerides (MCT) and isopropyl myristate (IPM)
- IPM:MCT weight ratio 3:1 to 12:1
This defines a specific oil blend class and ratio window. It is a common design-around axis because many dermal emulsions use different esters/esters+silicones/MCT ratios.
Claim 6: Additional discontinuous oil phase (non-solvent oil)
- Claim 6: polyaphron dispersion further comprises an additional discontinuous phase comprising a non-solvent oil.
This can broaden coverage if a competitor uses extra oil structuring, but it can also create a narrower technical profile for proving “non-solvent oil” status.
Claim 7: Multi-oil-phase partitioning assignment (first/second/optional third)
- Claim 7: Discontinuous oil phases include:
- first discontinuous phase
- second discontinuous phase
- optionally a third discontinuous phase comprising mineral oil
- Distribution requirements:
- ≥ 60 wt% of calcipotriol in the first discontinuous phase
- ≥ 60 wt% of betamethasone dipropionate in the second discontinuous phase
- ≥ 60 wt% of alpha-tocopherol + BHA in the first discontinuous phase, or predominantly in first+second collectively
This is a key claim for infringement because it imposes a component-by-component location map across two distinct oil phases.
Claim 8: Specific identity of oil blends in both phases
- Claim 8: first and second discontinuous phases each comprise the same pharmaceutically acceptable oil:
- a blend of caprilic capric triglycerides (CCT) and isopropyl myristate (IPM)
- IPM:CCT ratio 3:1 to 12:1
This overlaps with claim 5 but is stricter: both phases must use the same oil blend class at a ratio range.
Claim 9: Continuous aqueous phase alcohol content (isopropanol)
- Claim 9: continuous aqueous phase comprises at least 4 wt% isopropanol
This limits the aqueous formulation matrix. For design-around, switching co-solvents or lowering isopropanol below 4 wt% is a direct axis.
Claim 10: Chemical stability time-temperature window
- Claim 10: composition chemically stable for:
- ≥ 6 months at 25° C ±2° C, at 60% RH ±5%, and/or
- ≥ 12 months at 5° C ±3° C, at 60% RH ±5%
This is a performance attribute that can become enforceable via evidence-based claim construction. Many infringement cases for formulation claims treat stability as requiring test proof of the accused product under specified conditions.
Claim 11: Non-solvent oil identity
- Claim 11: non-solvent oil comprises mineral oil.
This is a narrowing of claim 6’s “non-solvent oil” class.
How do the claims map to “design-around” options?
High-risk infringement zones (hard to avoid without changing core technology)
-
Polyaphron microstructure
If a competitor uses non-polyaphron emulsions, nanoparticles, liposomes, or simple emulsions without discontinuous oil phase microstructure consistent with polyaphron, they can avoid the structural premise. If they do use polyaphron, they still must hit the actives/excipients/pH.
-
pH window (7.25–8.25 in claim 1; ~7.5–8.0 in claim 2)
Reproducing pH outside the claimed range avoids claim 1/2.
-
Quantitative presence of antioxidants
- alpha-tocopherol: 0.001–0.005 wt%
- BHA: 0.05–0.5 wt%
Many competitors change antioxidant selection (different phenolics, different solubilizers) or omit BHA.
-
Isopropanol minimum (claim 9)
Lowering isopropanol below 4 wt% can avoid claim 9 while still remaining in claim 1 if claim 9 is not required for infringement.
“Often litigated” formulation facts: phase partitioning and multi-oil assignment
- Claims 4 and 7 require where components reside in discontinuous oil phases.
- Competitors can attempt to shift partitioning by altering oil composition, polarity, surfactant system, droplet size distribution, or presence of additional solvents.
- In practice, parties will need methods to quantify distribution among phases (e.g., separation protocols, analytical quantification). These evidentiary requirements raise the practical risk of “almost the same” formulations.
Oil selection and ratios
- Claims 5 and 8: IPM with MCT/CCT at IPM:CCT (or IPM:MCT) 3:1 to 12:1.
- Design-around: change oil pair, use different ratio outside range, or introduce silicone oils or other esters that shift solubility.
What does the claim set suggest about the patent’s technical theory?
The claim architecture indicates a two-level strategy:
-
Macro-constraints (Claim 1 and Claim 2/3/9)
- polyaphron dispersion
- defined actives and antioxidants concentration ranges
- specified pH and alcohol level
- chemical stability attributes
-
Micro-constraints (Claims 4, 7, 5, 8, 6, 11)
- ensure specific components preferentially reside in designated oil phases
- use specific oil blends (CCT/IPM, MCT/IPM)
- allow multi-oil-phase systems, including mineral oil as a third phase
This combination points to a formulation that is trying to improve stability and/or skin delivery by controlling solubility and localization of calcipotriol vs betamethasone dipropionate and antioxidants.
US 11,696,919 patent landscape: what can be concluded from the claim text alone?
Only limited landscape conclusions are possible because you have provided only the claims excerpt. A complete landscape requires the issued patent’s bibliographic data, prosecution history, family members, and Orange Book/FDA linkage. Under the constraints here, the only defensible landscape elements are those implied by the claim scope itself:
- The patent is positioned as a formulation technology around polyaphron topical delivery for a calcipotriol/betamethasone dipropionate combination.
- The protected material is likely to be cross-referenced in licensing and FTO as a formulation-IP barrier around:
- oil-phase architecture
- antioxidant system selection
- pH and isopropanol concentration
- stability
Any broader “family” or “competitor” mapping is not determinable from your excerpt.
Key “scope in one table” for fast infringement screen
| Claim |
What must be true for infringement of that claim |
Key numeric limits |
| 1 |
Topical composition with polyaphron dispersion (continuous aqueous + discontinuous oil) |
calcipotriol 0.001–0.01 wt%, betamethasone dipropionate 0.001–0.01 wt% (per your text), alpha-tocopherol 0.001–0.005 wt%, BHA 0.05–0.5 wt%, pH 7.75 ±0.5 |
| 2 |
Claim 1 + tighter pH |
pH 7.75 ±0.25 |
| 3 |
Claim 1 + betamethasone level |
betamethasone 0.02–0.1 wt% (per your text) |
| 4 |
Claim 1 + preferential localization in discontinuous oil |
≥60 wt% of at least one of: calcipotriol / betamethasone / alpha-tocopherol / BHA in discontinuous oil |
| 5 |
Claim 1 + specific oil blend |
discontinuous oil has MCT + IPM, IPM:MCT 3:1 to 12:1 |
| 6 |
Claim 1 + additional discontinuous phase with non-solvent oil |
non-solvent oil discontinuous phase added |
| 7 |
Claim 1 + two-phase assignment |
calcipotriol ≥60 wt% in first oil; betamethasone ≥60 wt% in second oil; alpha-tocopherol+BHA ≥60 wt% in first (or predominantly in first+second) |
| 8 |
Claim 7 + specific oil identity in both phases |
CCT + IPM; IPM:CCT 3:1 to 12:1 in first and second oil phases |
| 9 |
Claim 1 + aqueous co-solvent level |
continuous aqueous phase contains ≥4 wt% isopropanol |
| 10 |
Claim 1 + stability performance |
≥6 months at 25° C ±2° C (60% RH ±5%); and/or ≥12 months at 5° C ±3° C (60% RH ±5%) |
| 11 |
Claim 6 + identity of non-solvent oil |
non-solvent oil is mineral oil |
Key Takeaways
- US 11,696,919 claim 1 protects a polyaphron-based topical formulation combining calcipotriol and betamethasone dipropionate with controlled antioxidant chemistry (alpha-tocopherol and BHA) and a narrow pH band centered at 7.75.
- Dependent claims materially increase technical specificity by requiring phase partitioning (claims 4 and 7), specific oil systems and ratios (claims 5 and 8), and aqueous isopropanol levels (claim 9).
- The patent’s enforceability leverage is likely in disputes over:
- whether an accused product is truly a “polyaphron dispersion,” and
- whether distribution of calcipotriol and betamethasone (and antioxidants) matches the ≥60 wt% phase-location rules.
FAQs
-
What makes a product infringe claim 1 of US 11,696,919 besides having the same active ingredients?
Infringement depends on having a polyaphron dispersion with a continuous aqueous phase plus discontinuous oil phase(s), matching the specified ingredient concentration bands and the pH window.
-
How do claims 4 and 7 change the infringement burden?
They require quantitative evidence of where components reside, imposing ≥60 wt% localization of specified components in discontinuous oil phases (and claim 7 assigns calcipotriol and betamethasone to different oil phases).
-
Can a competitor avoid claim 9 without changing the rest of the formula?
Yes, lowering isopropanol in the continuous aqueous phase below 4 wt% targets claim 9 specifically.
-
Does claim 10 require a stability test performed exactly at the stated conditions?
Yes. The claim requires chemical stability for the stated durations under the stated temperature and RH ranges.
-
What are the most direct formulation “levers” to design around the oil-related claims?
Change oil identity or ratio outside the IPM: CCT (or IPM: MCT) 3:1 to 12:1 ranges, alter multi-oil-phase structure, or shift component partitioning so the ≥60 wt% phase-location rules are not met.
